Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Concept and feasibility assessment for AnandaCor, a fast melting tablet, as a diagnostic device in ischemic heart conditions.

Objective

Ananda Pharma GmbH qualified a plant derived active pharmaceutical ingredient (API) for specific heart diseases. In nanomolar doses the substance protects cardiomyocytes by stabilizing the Na+/K+ -ATPase. The API enables ischemic preconditioning and has a balancing effect on the energy metabolism of cardiomyocytes by enhancing the turnover of lactate to ATP. The specific mode of action conveys a larger therapeutic range which means a smaller risk for unwanted side effects compared to similar substances.

The API targets mainly on the small vessels and the myocardial cell, rather than on the large vessels, and therefore can be useful to distinguish between relevant obstructive coronary atherosclerosis and the actual ischemia in the microvasculature or in the myocardial cell itself. These properties convey the great potential as a new diagnostic medical device for patients with angina pectoris due to ischemic heart conditions.

Therefore Ananda Pharma GmbH developed AnandaCor®, an innovative tablet formulation of the active pharmaceutical ingredient.
Since cardiovascular and ischemic heart conditions are highly prevalent in all industrialized countries, with over 2 million deaths per year and estimated external costs of nearly 110 billion € per annum in the European Union alone, there is an urgent need for effective diagnostic investigation.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-SMEInst-2014-2015

See all projects funded under this call

Coordinator

ANANDA PHARMA GMBH
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 50 000,00
Address
KARL LIEBKNECHT STRASSE 94
14482 POTSDAM
Germany

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Brandenburg Brandenburg Potsdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 71 429,00
My booklet 0 0